Cancer Immunology and Immunotherapy [electronic resource] /
Dranoff, Glenn.editor.
The recent FDA approval of Provenge® as the first therapeutic cancer vaccine together with the recent demonstration that Ipilimumab®, a monoclonal antibody that blocks the negative immune checkpoint cytotoxic T lymphocyte associated antigen-4, prolongs patient survival are major achievements that usher in a new era of cancer immunotherapy. These "first-in-class" treatments reflect the substantive progress that basic and translational scientists have made towards understanding the mechanisms underlying protective tumor immunity in cancer patients Immunotherapies were first explored at the turn of the twentieth century, but the crafting of potent treatments required more detailed knowledge of how the immune system responds to cancer. Advances in genetic, cellular, and biochemical technologies have begun to yield this critical information, focusing attention on immune recognition, regulation, and escape. Indeed, the dynamic interplay of these processes in the tumor microenvironment is now recognized to play a decisive role in determining disease outcome. This volume highlights the rapid progress and breadth of research in cancer immunology, and provides a framework for anticipating many more clinical successes in cancer immunotherapy.
Description based upon print version of record.
Cancer Immunology and Immunotherapy; Preface; References; Contents; Contributors; Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control; 1 Introduction; 2 ``In Situ ́ ́ Immune Contexture, the Strongest Prognostic Factor for Recurrence and Overall Survival: The Case of Colorectal Cancer; 3 Induction of Functionally Active Tertiary Lymphoid Structures in the Vicinity of Tumoral Beds as Potential Sites of ``In Situ Immune Reactions: The Example of Lung Carcinoma
4 Subversion of Innate Immunity Receptors: Stimulation of Toll Like Receptors on Lung Carcinoma Cells Modulates Cell Survival and Response to Chemotherapy5 ``Paradoxical ́ ́ Control of Inflammation Influences Clinical Outcome in Head and Neck Cancer; 6 The Immune Reaction in a Tumor Developing in an Immuno-Privileged Site: The Case of Primary Intraocular Lymphoma; 7 Conclusions; References; Subversion and Coercion: The Art of Redirecting Tumor Immune Surveillance; 1 Introduction; 2 The Inflammatory Trio: TNF-α, TGF-beta, IL-6
3 The Local Trigger: IL-23 and IL-12 Balance in the Tumor Microenvironment4 Feeding the Inflammatory Niche: Adaptive T Cell Responses Fostering the Tumor; 5 Turning Foes into Friends, CD8+ T Cells Lose Their Teeth; 6 Inflammatory Control at the Tumor Site; 7 Conclusions; References; STAT3: A Target to Enhance Antitumor Immune Response; 1 Introduction; 2 Stat3-Mediated Immune Suppression; 2.1 Inhibition of the Th1 Immune Response; 2.2 Relevant Immunologic Signaling Pathways; 2.3 Role in Myeloid Derived Suppressor Cells; 2.4 Role in Regulatory T-Cells; 3 Therapeutic Relevance
3.1 Genetic Evidence and Potential Toxicity3.2 JAK Inhibitors; 3.3 Other Oncogenic Kinase Inhibitors; 3.4 RTK Inhibitors; 3.5 siRNA; 4 Concluding Remarks; References; Biology and Clinical Observations of Regulatory T Cells in Cancer Immunology; 1 Introduction; 2 Treg Lineage and Development; 3 Treg Subsets; 3.1 Cell Surface Markers of Mouse Tregs; 3.2 Cell Surface Markers of Human Tregs; 3.3 Toll Like Receptors Expressed by Tregs; 3.4 Functional Subsets of Tregs; 3.5 Treg-Derived Malignancies; 4 Mechanisms of Treg-Mediated Immune Suppression in Cancer
4.1 Immunosuppressive Cytokines and Factors4.2 Suppression by Direct Cell-Cell Contact; 4.3 Treg-Mediated Cytotoxicity; 5 Clinical Observations of the Association of Tregs with Cancer; 6 Modification of Treg Biology as Cancer Immunotherapy; 6.1 The Cellular Microenvironment; 6.2 Strategies to Modulate Treg Number and Function; 6.3 Attenuating Treg Function; 7 Conclusions; References; Concepts and Ways to Amplify the Antitumor Immune Response; 1 Introduction; 2 Pharmacology of Tumor Cell-Immune Cell Interactions; 3 Tumor Cell Development and Its Danger Signals; 3.1 Neoplastic Cells
3.2 Chronic Inflammation
Includes bibliographical references and index.
The recent FDA approval of Provenge® as the first therapeutic cancer vaccine together with the recent demonstration that Ipilimumab®, a monoclonal antibody that blocks the negative immune checkpoint cytotoxic T lymphocyte associated antigen-4, prolongs patient survival are major achievements that usher in a new era of cancer immunotherapy. These "first-in-class" treatments reflect the substantive progress that basic and translational scientists have made towards understanding the mechanisms underlying protective tumor immunity in cancer patients Immunotherapies were first explored at the turn of the twentieth century, but the crafting of potent treatments required more detailed knowledge of how the immune system responds to cancer. Advances in genetic, cellular, and biochemical technologies have begun to yield this critical information, focusing attention on immune recognition, regulation, and escape. Indeed, the dynamic interplay of these processes in the tumor microenvironment is now recognized to play a decisive role in determining disease outcome. This volume highlights the rapid progress and breadth of research in cancer immunology, and provides a framework for anticipating many more clinical successes in cancer immunotherapy.
Cancer research.
Immunology.
Cancer Research.
Immunology.
Current topics in microbiology and immunology